MusclePharm Performance
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and MusclePharm are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days MusclePharm has generated negative risk-adjusted returns adding no value to investors with long positions. Even with relatively invariable basic indicators, MusclePharm is not utilizing all of its potentials. The current stock price agitation, may contribute to short-term losses for the retail investors. ...more
| Begin Period Cash Flow | 2 M | |
| Total Cashflows From Investing Activities | -2000.00 |
MusclePharm |
MusclePharm Relative Risk vs. Return Landscape
If you would invest (100.00) in MusclePharm on November 16, 2025 and sell it today you would earn a total of 100.00 from holding MusclePharm or generate -100.0% return on investment over 90 days. MusclePharm is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than MusclePharm, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
MusclePharm Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of MusclePharm for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for MusclePharm can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| MusclePharm is not yet fully synchronised with the market data | |
| MusclePharm has some characteristics of a very speculative penny stock | |
| MusclePharm has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 50.04 M. Net Loss for the year was (12.87 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MusclePharm generates negative cash flow from operations |
MusclePharm Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of MusclePharm Pink Sheet often depends not only on the future outlook of the current and potential MusclePharm's investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. MusclePharm's indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 41.2 M | |
| Cash And Short Term Investments | 1.2 M |
MusclePharm Fundamentals Growth
MusclePharm Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of MusclePharm, and MusclePharm fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on MusclePharm Pink Sheet performance.
| Revenue | 50.04 M | |||
| EBITDA | (7.07 M) | |||
| Total Debt | 10.71 M | |||
| Cash Flow From Operations | (8.04 M) | |||
| Total Asset | 11.21 M | |||
| Retained Earnings | (205.54 M) | |||
Things to note about MusclePharm performance evaluation
Checking the ongoing alerts about MusclePharm for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for MusclePharm help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| MusclePharm is not yet fully synchronised with the market data | |
| MusclePharm has some characteristics of a very speculative penny stock | |
| MusclePharm has a very high chance of going through financial distress in the upcoming years | |
| The company reported the revenue of 50.04 M. Net Loss for the year was (12.87 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| MusclePharm generates negative cash flow from operations |
- Analyzing MusclePharm's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether MusclePharm's stock is overvalued or undervalued compared to its peers.
- Examining MusclePharm's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating MusclePharm's management team can have a significant impact on its success or failure. Reviewing the track record and experience of MusclePharm's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of MusclePharm's pink sheet. These opinions can provide insight into MusclePharm's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Consideration for investing in MusclePharm Pink Sheet
If you are still planning to invest in MusclePharm check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the MusclePharm's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance |